Open AccessPredicting grade of cerebral gliomas using Myo-inositol/Creatine ratio
Author(s) -
Lamiaa I. A. Metwally,
Sally Emad El-din,
Omar Abdelaziz,
Iman M. Hamdy,
Amr K. Elsamman,
Ahmed Abdelalim
Publication year - 2014
Publication title -
the egyptian journal of radiology and nuclear medicine /the egyptian journal of radiology and nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.19
H-Index - 13
eISSN - 2090-4762
pISSN - 0378-603X
DOI - 10.1016/j.ejrnm.2013.07.004
Subject(s) - medicine , anaplastic astrocytoma , grading (engineering) , glioma , biopsy , lesion , astrocytoma , creatine , radiology , nuclear medicine , pathology , civil engineering , cancer research , engineering
PurposeOur aim was to determine the diagnostic accuracy of MI/Cr ratio in determining the grade of glioma.Materials and methodsTwenty-two patients (14 males and 8 females), ranging in age from 15–63years (mean 34.4years) were prospectively recruited for this study. All had a brain tumor recently diagnosed by MRI and had received no previous treatment, except for steroids. They were referred for MRS examination before surgical biopsy and/or resection or radiotherapy. Ratios for MI/Cr, Cho/Cr, and Cho/NAA were obtained for each lesion and compared with the grade of the lesion.ResultsThe levels of MI/Cr were higher (2.14±1.4) in patients with low-grade astrocytoma, and lower in patients with anaplastic astrocytoma (0.39±0.11) and GBM (0.025±0.06). 21 out of the 22 patients were correctly classified using MI/Cr ratio, one patient was misdiagnosed as high grade glioma and the biopsy revealed grade II glioma. The diagnostic accuracy, sensitivity and specificity of MI/Cr ratio for the grading of glioma was 95.4%, 100%, and 92.8%, respectively.ConclusionMRS has proven to be an important complementary tool saving the patient from unnecessary biopsy taking when it is conclusive thus altering the treatment planning. This study had demonstrated that MI level and MI/Cr ratio are important in presurgical grading of brain tumors